Cardiol Therapeutics Inc., founded on January 19, 2017 in Ontario, Canada, is a clinical-stage biotechnology company focused on the research and clinical development of innovative anti-inflammatory therapies for the treatment of cardiovascular diseases. The company's lead product, CardiolRx, a medicinal oral cannabidiol formulation, is conducting an outcome study of hospitalized patients who have tested positive for the COVID - 19 virus. This potential registration trial aims to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events in COVID patients with a prior history of CVD or risk factors, and to investigate the impact of CardiolRx as a key marker of inflammatory heart disease.
